Akari Therapeutcis (AKTX) Regains Nasdaq Compliance

Akari Therapeutics, Plc (Nasdaq: AKTX) announces receipt of written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the Company that its deficiency under Listing Rule 5550(b) has been cured. The Company is now in full compliance with all Nasdaq continued listing requirements.

Based on the foregoing, the previously scheduled Nasdaq hearing before the Hearings Panel on November 21, has been cancelled. The Company will continue to be traded on The Nasdaq Capital Market.

“This is an important administrative hurdle for the company,” said Samir Patel, MD, Akari’s Interim President & CEO. “Ensuring that the Company maintains compliance with the Nasdaq listing requirements is of the utmost importance to our shareholders and we take this very seriously. We are very satisfied to put this matter behind us and move forward focusing on execution of our business strategy.”

You May Also Be Interested In

• Apple (AAPL) call put ratio 1.1 calls 1 put into hosting a special event
• Silicon Labs opens new R&D lab in Austin with $23M state grant
• Jones Trading Starts Xtend AI Robotics (XTND) at Buy